Bright Minds Biosciences Inc.

NASDAQ:DRUG

Biotechnology

Healthcare
$20.76 +1.04%

+$0.62 today

Market cap
$204.78M
Beta
-0.11
P/E (TTM)
-29.8
EPS (TTM)
-$2.87
52W Low $23.18High $123.75

Volume 0.14M

Average 0.27M

DRUG Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Bright Minds Biosciences Inc.NASDAQ: DRUG

Net Income · Q2 FY2026 · quarter ended Mar 2026

Net income grows, but more slowly than its trailing trend

Q2 FY2026 net income of CA$10.63M (cash outflow) rose 260.4% year over year, behind the +699.2% change in trailing-twelve-month net income. Sequentially, it rose 40.6% from the prior quarter. Over 3 fiscal years it compounded at -6.5% a year.

Context

  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate of -CA$44.87M (+266.9%) for the fiscal year ending Sep 2026, a slowdown from the +336.5% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$10.63M+40.6% QoQ
Last fiscal yearSep 2025
-CA$12.23M+336.5% YoY
LTMMar 2026
-CA$27.53M+699.2% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+260.4%+227.3%-33.1 pp
1 year+336.5%+266.9%-69.5 pp
3-year CAGR-6.5%+93.6%+100.1 pp
5-year CAGR+37.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

CAD · from the cash flow

Latest · FY2025
(12.23M) CAD
Year-over-year change
-336.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How DRUG compares with its peers on the latest reported figures

No competitor Net Income figures are available to compare.

Cash Flow Statement

CAD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Net Income(8.65M)(14.96M)(7.37M)(2.8M)(12.23M)
Depreciation & Amortization06.04K72.45K73.36K76.87K
Deferred Income Tax00000
Stock-Based Compensation880.62K875.06K1.15M839.77K3.18M
Change in Working Capital306.08K724.13K(941.72K)39.81K554.99K
Accounts Receivables(110.15K)(45.63K)118.8K(13.24K)(362.85K)
Inventory00000
Accounts Payables00000
Other Working Capital416.23K769.77K(1.06M)53.06K917.84K
Other Non-Cash Items144.76K(227.4K)65.1K(1.18K)(276.84K)
Operating Cash Flow(7.32M)(13.59M)(7.02M)(1.85M)(8.69M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow00000
Debt Repayment0(7.16K)(86.11K)(89.73K)(100.15K)
Common Stock Issued27.74M4.03M1.22M900.3K86.03M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.69M)1.17M1.06M0(360.14K)
Financing Cash Flow26.06M5.2M2.19M810.57K85.57M
Effect of Forex Changes223.79K258.82K(45.35K)11.72K312.63K
Net Change in Cash18.96M(8.13M)(4.88M)(1.03M)77.19M
Free Cash Flow(7.32M)(13.59M)(7.02M)(1.85M)(8.69M)

Bright Minds Biosciences Inc.

NASDAQ:DRUG

Intrinsic Alpha fair value

Locked

Current Price

$20.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.